Medical News

RSS

Needle-free natural vaccine against malaria: Research

A study published in the journal Science Translational Medicine proposes that preventative treatment with affordable and safe antibiotics in people living in areas with intense malaria transmission has the potential to act as a 'needle-free' natural vaccine against malaria and may likely provide an additional valuable tool for controlling and/or eliminating malaria in resource-poor settings.

12 Aug 2010

Today's Opinions and Editorials: The importance of following health reform's plan and more about 'death panels'

Within a few years, 6 million uninsured California residents will finally get medical coverage as part of the newly passed federal health care reforms. But what will they pay? And who will regulate premiums as insurers angle for customers? (8/11).

12 Aug 2010

Smoking rates continue to fall in Japan

Japan has set a world record with the 15th consecutive year of low smoking rates according to a nationwide survey released Wednesday by Japan Tobacco Inc.

11 Aug 2010

Rural health suffering in Australia

A report looking into the state of Australia's rural health system has found severe disparities in rural health care. The report shows that more than 52 percent of rural Australians are waiting one or more weeks for a routine appointment with their GP and some are forced to wait up to six months to see specialists.

11 Aug 2010

Mental health bill for 2008 was $5.3 billion: Report

According to the Australian Institute of Health and Welfare (AIHW), the country is spending more and more to deal with its mental ailment burden. This emerged from a report from the AIHW saying that finances spent on mental health services between 2007 to 2008 were $5.3 billion. Of this around 60 per cent came from state and territory governments, 36 per cent from the Commonwealth, and the rest from private health funds.

11 Aug 2010

HemaQuest commences HQK-1004 global Phase 2 clinical trial in EBV-related malignancies

HemaQuest Pharmaceuticals announced today that it has initiated the Company's Phase 2 clinical trial evaluating its proprietary HQK-1004 therapy for the treatment of lymphomas and related cancers associated with Epstein-Barr virus (EBV) infection. These EBV-related cancers have poor prognoses and short patient survival. Currently available cancer therapies are typically much less effective in patients with EBV-related lymphoid malignancies than in patients who have similar cancers not infected with the virus.

11 Aug 2010

Advanced Life Sciences second-quarter net loss decreases to $2.1 million

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced its financial results for the second quarter ended June 30, 2010.

11 Aug 2010

Elsevier launches Global Malaria Resource

Elsevier, the world-leading publisher of scientific, technical and medical information products and services, today announced the launch of Malaria Nexus, Elsevier's Global Malaria Resource, http://www.malarianexus.com.

11 Aug 2010

Anesthesia Business Consultants launch F1RSTAccess mobile application

Anesthesia Business Consultants, LLC is singly focused on servicing their clients. ABC exploits the latest technological advancements to maximize information sharing with their clients. In line with this philosophy, ABC proudly announces the launch of their mobile application, F1RSTAccessTM.

11 Aug 2010

Canadian Olympic figure skater's struggle with clear vision

Canadian figure skater, and Olympic bronze medalist Joannie Rochette - who captured the hearts of people worldwide with her stunning performance at the 2010 Vancouver Winter Olympics - is offering fans a rare glimpse into her past and her struggle with clear vision.

11 Aug 2010

Shire announces divestiture of Daytrana to Noven Pharmaceuticals

Shire plc, the global specialty biopharmaceutical company, announced the divestiture of Daytrana (methylphenidate transdermal system) to Noven Pharmaceuticals, Inc. Daytrana, which is approved and marketed in the US for the treatment of Attention Deficit Hyperactivity Disorder in children and adolescents, will continue to be available for patients through Noven.

11 Aug 2010

Derycz Scientific subsidiary secures exclusive article reprints and ePrints services contract for JAMA

Derycz Scientific, Inc., a company that is pioneering a fresh way of facilitating the flow of information from content publishers to enterprise customers and their constituents, today announced that its subsidiary, Reprints Desk, has secured an exclusive, multi-year contract to provide article reprints and ePrints services for the Journal of the American Medical Association, the nine specialty Archives Journals published by the American Medical Association, American Medical News, and Disaster Medicine and Public Health Preparedness.

11 Aug 2010

Healthcare professionals should use arts, humanities to improve mental healthcare practice: New book

Doctors and other healthcare professionals should use the arts and humanities to develop their empathic skills and improve mental healthcare practice, according to a new book.

11 Aug 2010

Sugary drinks do not promote weight gain in overweight women: Research

New research from Queen Margaret University, Edinburgh, shows that sugary drinks, consumed in moderate quantities, do not promote weight gain, carbohydrate craving or adverse mood effects in overweight women when they do not know what they are drinking.

11 Aug 2010

Ohio State University procures IonFlux 16 high throughput automated patch clamp instrument

Fluxion Biosciences, Inc. announced today that the Ohio State University Department of Pharmacology has purchased the IonFlux 16, the first high throughput automated patch clamp instrument of its kind geared towards the academic researcher. The IonFlux instrument will enable large scale pharmacology experiments on this group's nAChR targets, which previously were not feasible using a manual patch clamp rig.

From Fluxion Biosciences 11 Aug 2010

Dicerna announces closing of $25 million Series B round of financing

Dicerna Pharmaceuticals, Inc., a second generation RNA interference company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology™ and Dicer Substrate siRNA molecules, today announced that it has closed a $25 million Series B round of financing. New investor Domain Associates led the round, with all existing investors participating - Oxford Bioscience Partners, Skyline Ventures and Abingworth.

11 Aug 2010

PolyMedix's PMX-60056 Phase 1B/2 dose-ranging clinical study for heparin reversal meets study endpoints

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a Phase 1B/2 dose-ranging clinical study with PMX-60056, a synthetic small-molecule designed to reverse heparin and low molecular weight heparin anticoagulants.

11 Aug 2010

IPC The Hospitalist announces acquisition of Hospital Internists of Bristol

IPC The Hospitalist Company, Inc., a leading national hospitalist physician group practice company, announced today that it has acquired Hospital Internists of Bristol, LLC. Based in Bristol, Connecticut, the acquisition builds on IPC's established presence in the New England market.

11 Aug 2010

InspireMD announces availability of new delivery system for MGuard stent

InspireMD Ltd. is announcing today the availability of a new and improved delivery system for its MGuard coronary stent system. The new delivery system, which has already been introduced in selected regions around the world, will now make its launch in South America during SOLACI 2010, taking place at the Hilton Hotel in Buenos Aires, Argentina, August 11th-13th.

11 Aug 2010

Rxi Pharmaceuticals second-quarter net loss decreases to $2.1 million

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, today reported its financial results for the second quarter ended June 30, 2010.

11 Aug 2010